GRFS, OCR And A, 3 Health Services Stocks Pushing The Industry Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.0%) at 16,964 as of Wednesday, July 2, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,180 issues advancing vs. 1,847 declining with 143 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is unchanged. Top gainers within the industry include Abbott Laboratories ( ABT), up 1.3%, ResMed ( RMD), up 1.2%, Fresenius Medical Care AG & Co. KGaA ( FMS), up 0.8%, WellPoint ( WLP), up 0.7% and Aetna ( AET), up 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Grifols ( GRFS) is one of the companies pushing the Health Services industry lower today. As of noon trading, Grifols is down $0.23 (-0.5%) to $44.24 on light volume. Thus far, 149,560 shares of Grifols exchanged hands as compared to its average daily volume of 684,700 shares. The stock has ranged in price between $44.07-$44.64 after having opened the day at $44.64 as compared to the previous trading day's close of $44.47.

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, Canada, and internationally. Grifols has a market cap of $15.1 billion and is part of the health care sector. Shares are up 23.1% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Grifols a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Grifols as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Grifols Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Omnicare ( OCR) is down $0.69 (-1.0%) to $66.08 on light volume. Thus far, 259,624 shares of Omnicare exchanged hands as compared to its average daily volume of 965,400 shares. The stock has ranged in price between $66.00-$66.54 after having opened the day at $66.50 as compared to the previous trading day's close of $66.77.

Omnicare, Inc. operates as a healthcare services company that specializes in the management of pharmaceutical care in the United States and Canada. It operates through two segments, Long-Term Care Group and Specialty Care Group. Omnicare has a market cap of $6.6 billion and is part of the health care sector. Shares are up 10.6% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts that rate Omnicare a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Omnicare as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Omnicare Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Agilent Technologies ( A) is down $0.30 (-0.5%) to $57.95 on light volume. Thus far, 686,856 shares of Agilent Technologies exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $57.90-$58.59 after having opened the day at $58.22 as compared to the previous trading day's close of $58.25.

Agilent Technologies, Inc. provides bio-analytical and electronic measurement solutions and services to the life sciences, chemical analysis, diagnostics and genomics, communications, and electronics industries worldwide. Agilent Technologies has a market cap of $19.1 billion and is part of the health care sector. Shares are up 1.9% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Agilent Technologies a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Agilent Technologies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Agilent Technologies Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Baidu Stock Plummets After COO Qi Lu Resignation

Baidu Stock Plummets After COO Qi Lu Resignation

Wondering What Blockchain Technology Really Is? This Expert Explains It All

Wondering What Blockchain Technology Really Is? This Expert Explains It All

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

Dow Rises Sharply as U.S.-China Trade Tensions Thaw

GE Confirms $11.1 Billion Transportation Merger With Wabtec

GE Confirms $11.1 Billion Transportation Merger With Wabtec

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That

Gold Prices Look 'Rich' at Current Levels - Here's What Could Change That